Upcoming event

Tags

5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive disease, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Comorbidity, Cystectomy, Early recurrence patterns, EAU21, EAU22, EMUC21, EMUC22, EORTC, ERBB2, ERCC2, ESMO21, ESOU21, ESOU22, Gene expression analysis, Guidelines, Hematuria, High-risk NMIBC, Highlight of the Month, Immune checkpoint, Immune checkpoint blockade, Immunoregulation, Immunotherapy, Intravesical therapy, Laparoscopic radical cystectomy, Masterclass, Masterclass on MIBC, Masterclass on NMIBC, Meta-analysis, Metastatic urothelial cancer, MIBC, Microscopic haematuria, Molecular subtypes, Multiparametric MRI, Neoadjuvant, Neoadjuvant chemotherapy, Neoplasm recurrence, Nephroureterectomy, NIBC, Non-visible haematuria, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, PD-L1, Pembrolizumab, PET, PLND, Postoperative complications, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, Surgical video, Surgical videos, Systematic review, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, Urinary bladder neoplasms, Urinary diversion, Urological surgery, UROonco24, Urothelial cancer, Urothelium, UROwebinar, UTUC, Webinar
Show all

Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

The effect of a neoadjuvant instillation of chemotherapy in the prevention of recurrences of non-muscle invasive bladder cancer. Preliminary results of the PRECAVE prospective, controlled, randomized clinical trial

A randomized clinical trial of intravesical instillation of MMC and combination of MMC and Ara-C in non-muscle invasive bladder cancer

Safety evaluation of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: MITOBCG study (EUDRACT Number 2017-004540-37) preliminary results

PURE-02: An open-label, single-arm, feasibility study of neoadjuvant pembrolizumab before Radical Nephroureterectomy (RNU) in patients with high-risk, Upper-Tract Urothelial Carcinoma (UTUC)

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

European Urology Oncology, February 2021

Radical cystectomy against intravesical BCG for high-risk high-grade non-muscle invasive bladder cancer: Results from the randomized controlled BRAVO-feasibility study

Journal of Clinical Oncology, January 2021

A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE)

SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy

A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA)

Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer

BJU International, January 2021

Common germline-somatic variant interactions in advanced urothelial cancer

Nature Communications, December 2020

PreviousNext